2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4600 Wearable device vital sign monitoring in opti-AML, a randomized trial of older newly diagnosed AML patients

Rebecca L Olin, MD, MacKenzie Tweardy2, Ying Huang, MA, MS3, Tara L. Lin, MD4, Shivani Handa, MD5, Ronan Swords, MD6, Curtis Lachowiez, MD7, Elie Traer, MD, PhD8, Wendy Stock, MD9, Olatoyosi Odenike Jr, MD10, Anand Ashwin Patel, MD11, Maria R. Baer, MD12, Vu Duong, MD13, Eytan M Stein I, MD14, William Blum, MD15, Colin Vale16, Emily Curran, MD17, Yazan F. Madanat, MD18, Gary J. Schiller, MD19, Angela Nichols, NP20, Lacey Williams, MD21, Nyla Heerema, MD22, Timothy Chen, PhD23, Sonja Marcus, MPH24, Molly Martycz25, Mona Stefanos, MD, MBChB26, Leonard Rosenberg, PhD, RPh27, Louis DeGennaro, PhD28, Lore Gruenbaum, PhD29, John Byrd, MD30, Brian Druker, MD31, Ross L. Levine, Prof. Dr.32, Ashley Yocum, PhD33, Alice Scott Mims, MD34, Joshua F. Zeidner, MD35, Uma Borate, MBBS, MSc36
1 University of California San Francisco, San Francisco, California, United States
2 DataDive LLC, Chicago, Illinois, United States
3 The Ohio State University, Columbus, Ohio, United States
4 University of Kansas Medical Center, Kansas City, Kansas, United States
5 The Ohio State University, Columbus, Ohio, United States
6 Oregon Health & Science University, Portland, Oregon, United States
7 Oregon Health & Science University, Portland, Oregon, United States
8 Oregon Health & Science University, Portland, Oregon, United States
9 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
10 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
11 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
12 University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
13 University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
14 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
15 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
16 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
17 University of Cincinnati, Cincinnati, Ohio, United States
18 University of Texas Southwestern Medical Center, Dallas, Texas, United States
19 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
20 University of North Carolina, Chapel Hill, North Carolina, United States
21 University of North Carolina, Chapel Hill, North Carolina, United States
22 The Ohio State University, Columbus, Ohio, United States
23 The Ohio State University, Columbus, Ohio, United States
24 Blood Cancer United, Washington, District of Columbia, United States
25 The Ohio State University, Columbus, Ohio, United States
26 The Ohio State University, Columbus, Ohio, United States
27 Blood Cancer United, Washington, District of Columbia, United States
28 Blood Cancer United, Washington, District of Columbia, United States
29 Blood Cancer United, Washington, District of Columbia, United States
30 University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
31 Oregon Health & Science University, Portland, Oregon, United States
32 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
33 Blood Cancer United, Washington, District of Columbia, United States
34 The Ohio State University, Columbus, Ohio, United States
35 University of North Carolina, Chapel Hill, North Carolina, United States
36 The Ohio State University, Columbus, Ohio, United States

Introduction: Limited data exist regarding the utility of wearable devices for vital sign monitoring of AML patients who are undergoing treatment. Prior studies have been conducted in heterogenous patient populations and have combined both inpatient and outpatient monitoring. We aimed to investigate the utility of outpatient vital sign monitoring with a wearable device in newly diagnosed older AML patients receiving azacitidine and venetoclax (Aza/Ven) in the context of the randomized OPTI-AML study.

Methods: OPTI-AML was a randomized phase 2 study investigating Aza 75 mg/m2 x 7 days + Ven daily x 14 vs. 28-days for 2 cycles in newly diagnosed older  60 years) AML patients as previously reported (Borate et al, Blood 2026). As an exploratory objective of this study, participants were supplied with a VivaLNK biosensor patch, a medical grade FDA-cleared wearable device for continuous passive collection of physiological data including heart rate, respiratory rate, skin temperature, activity level and body position. Participants were asked to wear the biosensor patch from day 1 if treatment started outpatient or upon discharge if treatment started inpatient, for up to 2 cycles. The device’s data were securely transmitted to the study sponsor. Compliance reports were sent to the sponsor weekly and to sites bi-weekly. Electronic Patient Reported Outcomes (ePRO, consisting of MD Anderson Symptom Inventory and PROMIS Physical Function) were also collected at weekly intervals, with fatigue collected daily. The ability of vital sign and ePRO data to predict adverse events (AE) reported on study was assessed using gradient-boosted tree models, a type of machine learning.

Results: Of 169 patients randomized on OPTI-AML between 2023-2025, 54 (32.0%) initiated outpatient monitoring with the VivaLNK wearable device and are included in this analysis. Participants had a median age of 74 (range 66-84), were 42.6% female, and 92.6% Caucasian; these were representative of the total OPTI-AML population. Overall, participants wore the VivaLNK device for 35.9% ± 40.2% (standard deviation) of their eligible time on study. The addition of compliance monitoring did not significantly improve overall data collection compliance (35.6% ± 40.1% pre-monitoring vs. 36.1% ± 40.4% post-monitoring). Compliance was higher during Cycle 1 than Cycle 2 of therapy (50.0% ± 42.4% vs. 24.9% ± 34.7%). There was little correlation between vital signs and ePRO metrics, with only 3 of 184 Spearman coefficients >=0.3. During the course of the study, 6329 AE were reported, of which 150 were serious; the most common AE were thrombocytopenia, anemia, hypokalemia and neutropenia. VivaLNK data were available for 347 AEs during the 7 days preceding and at the time of the event. Gradient-boosted tree models achieved the highest performance using combined vital sign and ePRO features (AUC = 0.80), while vital signs alone and heart rate alone also predicted AE occurrence similarly well (AUC ≥ 0.75). Using these features, the models identified signals associated with impending AE onset up to four days before the event.

Conclusions: In this prospective study of older adults with newly diagnosed AML, implementation of a wearable device to capture vital signs yielded relatively low compliance over a 2-month study period. Wearable device vital sign data did not correlate with ePRO. Vital signs + ePRO combined were the best predictor of AE occurrence, although vital signs alone and heart rate alone were also good predictors. One limitation of this study includes the use of all AE types in modeling, without sufficient sample size to analyze only non-hematologic or serious AE such as neutropenic fever or hospitalization. Ultimately, the overall low compliance rate limits conclusions that can be drawn from collected data; thus, it is possible that additional monitoring and follow-up could have provided a larger dataset for analysis. Additional efforts may be needed to evaluate qualitative reasons for low compliance, such as patient preference for device type. These data may provide a baseline for future studies of wearable devices in older adults with AML, with the goal of addressing whether such remote monitoring is beneficial in an age of decentralized trials.

Rebecca L Olin, MD: Roche/Genentech - Research Funding; AstraZeneca - Research Funding; Novartis - Research Funding; Janssen - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony)